Quick Answer
NEKTAR THERAPEUTICS reported Research And Development Expense of $117.33 million for the year ending 2025.
- NEKTAR THERAPEUTICS showed a decrease of -3.0% in Research And Development Expense from 2024 to 2025.
- This data is from NEKTAR THERAPEUTICS's annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2014: $36.70 million | Q3 2014: $34.20 million | Q4 2014: $38.49 million | Q1 2015: $47.01 million | Q2 2015: $45.41 million | Q3 2015: $43.23 million | Q4 2015: $47.14 million | Q1 2016: $49.27 million | Q2 2016: $52.35 million | Q3 2016: $51.95 million | Q4 2016: $50.23 million | Q1 2017: $61.06 million | Q2 2017: $60.26 million | Q3 2017: $65.71 million | Q4 2017: $81.43 million | Q1 2018: $99.42 million | Q2 2018: $88.33 million | Q3 2018: $102.90 million | Q4 2018: $108.88 million | Q1 2019: $118.46 million | Q2 2019: $106.69 million | Q3 2019: $99.05 million | Q4 2019: $110.37 million | Q1 2020: $108.99 million | Q2 2020: $96.44 million | Q3 2020: $100.53 million | Q4 2020: $102.72 million | Q1 2021: $95.60 million | Q2 2021: $101.31 million | Q3 2021: $103.74 million | Q4 2021: $99.61 million | Q1 2022: $107.25 million | Q2 2022: $42.74 million | Q3 2022: $33.59 million | Q1 2023: $30.47 million | Q2 2023: $29.68 million | Q3 2023: $24.07 million | Q1 2024: $27.41 million | Q2 2024: $29.72 million | Q3 2024: $35.03 million | Q1 2025: $30.48 million | Q2 2025: $29.89 million | Q3 2025: $27.25 million.
- Over the full 17 years of available data (2009 to 2025), NEKTAR THERAPEUTICS's Research And Development Expense has grown by 23.4%.
- Historical annual values: Fiscal year 2025: $117.33 million | Fiscal year 2024: $120.91 million | Fiscal year 2023: $114.16 million | Fiscal year 2022: $218.32 million | Fiscal year 2021: $400.27 million | Fiscal year 2020: $408.68 million | Fiscal year 2019: $434.57 million | Fiscal year 2018: $399.54 million | Fiscal year 2017: $268.46 million | Fiscal year 2016: $203.80 million | Fiscal year 2015: $182.79 million | Fiscal year 2014: $147.73 million | Fiscal year 2013: $190.01 million | Fiscal year 2012: $148.68 million | Fiscal year 2011: $126.77 million | Fiscal year 2010: $108.07 million | Fiscal year 2009: $95.11 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: